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Inhibitorycoreceptorsarethoughttoplayimportantrolesinmaintainingimmunologicalhomeostasis,andadefectinthenegative
signals from inhibitory coreceptors may lead to the development of autoimmune diseases. We have recently identiﬁed B and
T lymphocyte attenuator (BTLA), a new inhibitory coreceptor expressed on immune cells, and we suggest that BTLA may be
involved in the development of autoimmune diseases using BTLA-deﬁcient mice. However, the role of BTLA in the pathogenesis
of autoimmune diseases in humans remains unknown. We, therefore, examined the possible association between BTLA and
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sj¨ ogren’s syndrome (SS) by conducting a case-control genetic
association study. We found that 590C single-nucleotide polymorphism (SNP) of BTLA gene was signiﬁcantly associated with
susceptibility to RA, but not to SLE or SS. Furthermore, RA patients bearing this 590C SNP developed the disease signiﬁcantly
earlierthanthepatientswithoutthisallele.WealsofoundthatBTLAwith590Callelelackedtheinhibitoryactivityonconcanavalin
A- and anti-CD3 Ab-induced IL-2 production in Jurkat T cells. These results suggest that BTLA is an RA-susceptibility gene and is
involved in the protection from autoimmunity in humans.
1.Introduction
The immune system has developed multiple mechanisms
to prevent deleterious activation of T cells. One such
mechanism is the intricate balance between positive and
negative costimulatory signals delivered to T cells. The
B7-1 (CD80)/B7-2 (CD86)—CTLA-4 pathway is the best-
characterized inhibitory pathway for T cell suppression
and tolerance [1, 2]. Another inhibitory pathway involves
programmed death-1 (PD-1) [3], which interacts with PD-
L1 (also known as B7-H1) [4, 5] and PD-L2 (B7-DC) [6,
7]. Since these inhibitory coreceptors inhibit proliferation
and cytokine production of T cells in vitro and in vivo,
they are thought to play important roles in maintaining
immunological homeostasis.
A defect in the negative signals from inhibitory corecep-
tors may reduce the threshold of autoreactive lymphocyte
activation and, thus, may lead to the development of
autoimmune diseases. This notion has been evidenced by the
autoimmune phenotype or lymphocyte hyperreactivity in
geneticallymanipulatedmicethatlackCTLA-4andPD-1[8–
10]. In humans, CTLA-4 and PD-1 have been demonstrated
to be involved in the regulation of autoimmune diseases
by single nucleotide polymorphisms (SNPs) case-control
association studies. It has been demonstrated that SNPs in
PD-1 [11–13], but not in CTLA-4 [14], are associated with
susceptibility to systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA). On the other hand, SNPs in
CTLA-4 are associated with disease risk in Grave’s disease,
autoimmune hypothyroidism, and type I diabetes [15].
We have identiﬁed B and T lymphocyte attenuator
(BTLA) as an inhibitory coreceptor expressed on Th1 cells
and B cells in mice [16]. Subsequently, analyses using anti-
BTLA antibody have revealed that BTLA is expressed not2 Clinical and Developmental Immunology
only on CD4+ T cells and B cells but also on a wide range
of hematopoietic cells including CD8+ T cells, NKT cells, NK
cells, macrophages, and dendritic cells at various levels [17–
20]. BTLA contains a single extracellular immunoglobulin
(Ig) domain, a transmembrane region, and an intracellu-
lar region. There are two immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) in the intracellular region, and
both of them are involved in the association with SHP-1 and
SHP-2 [16, 21]. The ligand for BTLA is the TNF receptor
family member herpesvirus entry mediator (HVEM) [22–
24], which is broadly expressed on hematopoietic cells,
including T cells, macrophages, and dendritic cells (DCs)
[22]. Ligation of BTLA induces its tyrosine phosphorylation
and SHP-1/SHP-2 association and then attenuates IL-2 pro-
duction and proliferation of T cells [16, 21]. These ﬁndings
suggest that BTLA functions as an inhibitory coreceptor
through the interaction with HVEM and that HVEM-BTLA
interaction may play a role in the prevention of autoimmune
diseases.
We have shown that BTLA-deﬁcient (BTLA−/−)m i c e
exhibit increased speciﬁc antibody responses and enhanced
sensitivity to experimental autoimmune encephalomyelitis
[16]. In addition, we have recently shown that aged BTLA−/−
mice spontaneously develop autoantibodies and autoim-
mune hepatitis-like disease with lymphocytic inﬁltration
in multiple organs [25]. Moreover, it has recently been
demonstrated that SNP of BTLA is associated with RA
susceptibility in the Taiwanese population [26]. However,
the role of HVEM-BTLA pathway in the pathogenesis of
autoimmune diseases in humans is still largely unknown.
We, therefore, attempted to identify SNPs in the human
BTLA gene in the Japanese population and investigated its
association with susceptibility to autoimmune diseases. We
discovered two SNPs in the coding region of human BTLA
gene in the Japanese population. We also found that 590C
SNP was associated with susceptibility to RA but not to
SLE or Sj¨ ogren’s syndrome (SS). Furthermore, RA patients
bearing this 590C SNP developed the disease signiﬁcantly
earlier than the patients without this allele. We also found
that BTLA with 590C SNP lacked the inhibitory activity on
Jurkat T cells. Our results suggest that dysfunction of BTLA
is involved in the pathogenesis of RA.
2.MaterialsandMethods
2.1. Patients and Controls. A case-control genetic association
study was conducted to examine the association between
the BTLA gene and the development of RA, SLE, and
SS. Patients with RA (81 patients, 80.2% women), SLE
(64 patients, 95.3% women), and SS (60 patients, 95.0%
women)wererecruitedintothisstudyfromChibaUniversity
Hospital and Chiba-East National Hospital. All patients
fulﬁlled the American College of Rheumatology revised
criteria for RA [27]o rS L E[ 28] and the Ministry of Health
and Welfare criteria (1999 revision, Japan) for SS [29].
The ethics committee of the faculty of Chiba University
approved this study. Control subjects were 71 unrelated
healthy Japanese blood donors from the same geographic
area (91.5% women).
2.2. Patient Proﬁles. The titers of rheumatoid factor (RF),
matrix metalloproteinase-3 (MMP-3), C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), antinucleotide
antibody (ANA), immunoglobulin G (IgG), and comple-
ment 3 (C3) in sera of the patients were investigated at the
ﬁrst visit to the hospital. Age of disease onset was determined
according to medical records.
2.3. Screening for Mutations in the Open Reading Frame of
BTLA cDNA. Peripheral blood mononuclear cells (PBMCs)
were isolated from 20 healthy Japanese donors by Ficoll-
Paque (Amersham Biosciences, Uppsala, Sweden) density
gradient centrifugation. Total RNA was puriﬁed from
PBMCs using Isogen (Nippon gene, Toyama, Japan). First
strand of cDNA was synthesized by a First-Strand Beads kit
(Amersham Pharmacia biotech, Piscataway, NJ), and cDNA
of BTLA was ampliﬁed using Pyrobest DNA polymerase
(TaKaRa, Otsu, Japan). ExoSAP-IT-treated PCR products
(USB, Cleveland, OH) were sequenced using a Big-Dye
Terminators sequencing kit (Applied Biosystems, FosterCity,
CA) on an ABI PRISM 3100 Avant genetic analyzer (Applied
Biosystems) according to the manufacturer’s instruction.
Derived sequences were compared with reported human
BTLA cDNA sequences (DM004104 and NW 001838881.2)
in the National Center for Biotechnology Information
(NCBI) database.
2.4. SNP Genotyping. PBMCs were treated with proteinase
K and genomic DNA was puriﬁed by phenol-chloroform
extraction. To amplify the BTLA gene encompassing the
#590 or #800 SNP, PCR was performed using two sets of
primers; exon4S 5
 -TCCCTCCCCTTCCTTTTAGA-3
  and
exon4AS 5
 -AATAATGCCTGGCACATGGT-3
  were used
for the ampliﬁcation of exon 4 (for 590A/C), and exon5S 5
 -
TACCATGGCCGTAAGTGTCA-3
  and 3UT 5
 -GAGCCC-
AGACAATGATGTCA-3
  were used for the ampliﬁcation
of exon 5 (for 800T/C). PCR products were then directly
sequenced as described above. Heterozygous genotype was
determined by identiﬁcation of overlapping two short peaks
of each nucleotide in the sequencing data.
2.5. Cell Culture and Infection of Jurkat T Cells. Jurkat
T cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal calf serum and antibiotics. Human
BTLA gene with 590A or 590C was ampliﬁed from cDNA
derived from a donor who carries the 590A or 590C
using Pyrobest DNA polymerase with the following primers;
5
 -GAAGATCTTTTTTCCATCACTGATATGTGC-3
  and
5
 -CCGCTCGAGTCCCTGTTGGAGTCAGAAAC-3
 .P C R
products were isolated, digested with Bgl II and Xho I, and
ligated into the multiple cloning site of retroviral expression
vector Tb-lym-GFP RV [30], which contains an internal
ribosome entry site (IRES) between the multiple cloning site
and the green ﬂuorescent protein (GFP) to generate 590A
BTLA-IRES-GFP or 590C BTLA-IRES-GFP. Cloned vectors
were transfected into amphotropic Phoenix packaging cells
using FuGENE 6 transfection reagent (Roche, Indianapolis,
IN). Forty-eight hours after transfection, viral supernatantsClinical and Developmental Immunology 3
were harvested and used for infection to Jurkat T cells
in RetroNectin-coated plates (TaKaRa). Seven days after
infection, Jurkat T cells expressing GFP were sorted by
FACS Aria cell sorter (Becton-Dickinson, San Jose, CA).
After two sequential rounds of cell sorting, over 95% of
the cells were positive for GFP with similar levels of GFP
intensity. Retrovirus-infected Jurkat T cells were stained with
PE-conjugatedantihumanBTLAmAb(MIH26)(BioLegend,
San Diego, CA) for 60min on ice. After washing, cells
were analyzed on a FACSCalibur (Becton Dickinson) using
CellQuest Pro software (Becton Dickinson).
2.6. IL-2 Production Assay. Jurkat T cells (5 × 105 cells) that
express 590C BTLA or 590A BTLA were stimulated with
various concentrations of concanavalin A (ConA) (6.25–
50μg/mL) in ﬂat-bottomed plates that were coated with 2
× 105 of HVEM-expressing CHO cells (a kind gift from Dr.
K. M. Murphy, Washington University School of Medicine,
S t .L o u i s ,M O )[ 23] to costimulate BTLA on Jurkat T cells.
In other experiments, Jurkat T cells expressing 590C BTLA
or 590A BTLA were stimulated with immobilized anti-
CD3Ab (OKT3, 0.2μg/mL, BD PharMingen, San Diego, CA)
and various concentrations of immobilized anti-BTLA Ab
(MIH26, 0–20μg / m L ,e B i o s c i e n c e ,S a nD i e g o ,C A )i nt h e
presence of anti-CD28 Ab (CD28.2, 1μg/mL, BD PharMin-
gen). Twenty-four hours later, the culture supernatants
were harvested and IL-2 concentration was measured by a
human IL-2 ELISA kit (Biosource, Camarillo, CA) following
manufacturer’s instruction.
2.7. Statistical Analysis. The accord of SNP genotype dis-
tributions in each population with Hardy-Weinberg equi-
librium was evaluated using chi-square goodness-of-ﬁt test.
The distributions of SNPs were compared between patients
with RA, SLE, or SS and healthy controls by contingency
table analysis and chi-square test. Relative risk was calculated
as the ratio of incidence rates for 590A/A versus 590C SNP.
Clinical features of RA patients were compared between
the patients who carry 590A/A or 590C SNP using two-
tail Mann-Whitney’s U test. P-values less than .05 were
considered to be signiﬁcant.
3. Results
3.1. Discovery of SNPs in the Human BTLA Gene. To identify
SNPs in human BTLA gene, we isolated BTLA cDNA from
peripheral blood mononuclear cells (PBMCs) of healthy
Japanese donors (n = 20) and determined the sequences of
the open reading frame of BTLA cDNA. By comparing these
sequences with reported human BTLA cDNA sequences
(DM004104 and NW 001838881.2) in NCBI database, we
discovered two sequence variations (#590 and #800) in
human BTLA gene in Japanese population (Table 1). They
are localized in intracellular region of BTLA and cause
amino acid replacement (Table 1). Variations at #590 (A
to C) and #800 (T to C) were found in 15% and 40%,
respectively, (Table 1). On the other hand, we could not ﬁnd
any insertion or deletion in the open reading frame of BTLA
Table 1: Frequency of SNPs in BTLA gene in healthy Japanese
donors.
Nucleotide
no. Exon Original∗ Mutant
Amino
acid
change
Frequency
in
Japanese
590 IV A C Asn to Thr 15%
800 V T C Leu to Pro 40%
SNPs in human BTLA gene were determined in healthy Japanese donors
(n = 20) as described in Section 2.
∗Nucleotide of human BTLA gene reported in NCBI database (DM004104
and NW 001838881.2).
cDNA. Thus, we focused on #590 and #800 SNPs of BTLA
gene to determine whether these SNPs are associated with
susceptibility to autoimmune diseases.
3.2. Association of 590C SNP of BTLA Gene with Susceptibility
to Rheumatoid Arthritis. To determine whether #590 and
#800 SNPs of BTLA gene are involved in the susceptibility
to autoimmune diseases, we ﬁrst established a method that
distinguishes homozygous and heterozygous genotypes of
these SNPs. Genomic PCR was performed to amplify the
regionﬂankingeachSNPandthenucleotide(AorCfor#590
and T or C for #800) was then determined by sequencing the
PCR products directly.
We then examined the frequencies of these SNPs in
patients with RA (n = 81), SLE (n = 64), and SS (n = 60)
as well as in healthy controls (n = 71). The frequencies
of these SNPs of BTLA gene in patients with autoimmune
diseases and in healthy subjects are summarized in Table 2.
All groups are in Hardy-Weinberg equilibrium (data not
shown), indicating that these genotyping data are reliable.
Importantly, the frequency of individuals who carry 590
A/C or C/C genotype was signiﬁcantly increased in RA
patients but not in SLE patients and SS patients as compared
with healthy controls (30.9% in RA, 14.1% in SLE, 15.0%
in SS, and 14.1% in controls, Table 2). Statistical analysis
revealed that the carriage of the 590A/C or C/C genotype
was signiﬁcantly increased in RA patients (χ2 = 6.010,
P = .014, relative risk = 2.19, 95% CI 1.13–4.24). We also
found a signiﬁcant association between 590C allele and RA
susceptibility (χ2 = 5.881, P = .015, relative risk = 2.28,
95% CI 1.14–4.56, Table 3). On the other hand, we could not
detect any diﬀerence in the frequency of #800 SNP between
RA patients and healthy controls (Tables 2 and 3). These
results indicate that the carriage of 590C allele of BTLA gene
is signiﬁcantly associated with RA susceptibility and suggest
that BTLA is involved in the pathogenesis of RA.
3.3. Correlation of 590C Allele of BTLA Gene with Early Onset
of RA. We next compared disease proﬁles of RA patients
who carry 590A/C or 590C/C genotype with those of RA
patients who carry 590A/A genotype. RA patients with 590C
allele developed the disease at signiﬁcantly younger ages than
the patients without this allele (590C-41.1 ± 17.1 years old
versus 590A/A 49.9 ± 9.83 years old, P = .024), suggesting
that 590C allele of BTLA gene accelerates the development of4 Clinical and Developmental Immunology
Table 2: Association of 590A/C and 800T/C SNPs of human BTLA gene with susceptibility to autoimmune diseases.
590A/A 590A/C 590C/C χ2 P RR (95% CI)
Healthy subjects 61/71 (85.9%) 10/71 (14.1%) 0/71 (0.0%)
RA 56/81 (69.1%) 24/81 (29.6%) 1/81 (1.3%) 6.010 .014 2.19 (1.13–4.24)
SLE 55/64 (85.9%) 9/64 (14.1%) 0/64 (0.0%) 0.000 .997 1.00 (0.43–2.30)
SS 51/60 (85.0%) 9/60 (15.0%) 0/60 (0.0%) 0.022 .882 1.07 (0.46–2.45)
800T/T 800T/C 800C/C
Healthy subjects 36/71 (50.7%) 29/71 (40.8%) 6/71 (8.5%)
RA 45/87 (51.7%) 32/87 (36.8%) 10/87 (11.5%) 0.533 .766 0.98 (0.71–1.35)
SLE 35/56 (62.5%) 18/56 (32.1%) 3/56 (5.4%) 1.843 .398 0.76 (0.50–1.15)
SS 33/55 (60.0%) 16/55 (29.1%) 6/55 (10.9%) 1.885 .390 0.81 (0.54–1.21)
Genotyping of #590 and #800 SNPs of human BTLA gene was performed as described in Section 2.
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, SS: Sj¨ ogren’s syndrome,
RR: relative risk, CI: conﬁdence interval.
Table 3: Association of 590C allele of human BTLA gene with susceptibility to rheumatoid arthritis.
590 A Allele C Allele χ2 P RR (95% CI)
Healthy subjects 132 10
RA 136 26 5.881 .015 2.28 (1.14–4.56)
SLE 119 9 0.000 .997 1.00 (0.42–2.38)
SS 111 9 0.020 .887 1.07 (0.45–2.53)
800 T Allele C Allele χ2 P RR (95%CI)
Healthy subjects 101 41
RA 122 52 0.039 .844 1.04 (0.73–1.46)
SLE 88 24 1.822 .177 0.74 (0.48–1.15)
SS 82 28 0.364 .546 0.88 (0.58–1.33)
Same as the legend of Table 2.
RA. We also examined the titers of C-reactive protein (CRP),
rheumatoid factor (RF), and matrix metalloproteinase-3
(MMP-3) in sera of these RA patients at the ﬁrst visit to
thehospital (withoutmedicaltreatment).However,thetiters
of these inﬂammatory parameters were not signiﬁcantly
diﬀerent between RA patients with or without 590C allele
(Figure 1).
3.4. BTLA with 590C Allele Loses the Inhibitory Function
on ConA- or Anti-CD3-Induced IL-2 Production in Jurkat
TC e l l s .To examine the basis of 590C SNP of BTLA gene
for the susceptibility to RA, we compared the inhibitory
activity of 590C BTLA with that of 590A BTLA in vitro.
We employed Jurkat T cells to make stable transfectants
because Jurkat T cells did not express any detectable BTLA
mRNA even after activation (data not shown). Jurkat T
cells were infected with retrovirus of 590C BTLA-IRES-
GFP or 590A BTLA-IRES-GFP, and the infected cells were
sorted with coexpressed GFP using FACS. As shown in
Figure 2(a),thesortedJurkatTcellsexpressedsimilarlevelof
surface BTLA. These cells were then stimulated with various
concentrations of concanavalin A (ConA) for 24 hours in
the presence of HVEM-expressing CHO cells to costimulate
BTLA simultaneously [23]. ConA induced IL-2 production
from control virus (GFP-RV-) infected Jurkat T cells in
a dose-dependent manner (Figure 2(b)). As expected, IL-2
production was strongly inhibited in cells expressing 590A
BTLA (590A BTLA-IRES-GFP, Figure 2(b)). In contrast, in
cells expressing 590C BTLA (590C BTLA-IRES-GFP), IL-2
production was rather enhanced as compared with control
GFP-RV-infected cells (Figure 2(b)).
To further address the function of 590C BTLA, we
stimulated Jurkat T cells expressing 590A BTLA or 590C
BTLA with anti-CD3 Ab and various concentrations of
immobilized anti-BTLA Ab. As expected, anti-BTLA Ab
inhibited IL-2 production in cells expressing 590A BTLA
in a dose-dependent manner (Figure 2(c)). In contrast, in
cellsexpressing590CBTLAorcontrolGFP-RV-infectedcells,
anti-BTLA Ab did not signiﬁcantly inhibit IL-2 production
(Figure 2(c)). These results indicate that 590C BTLA lacks
the inhibitory function on IL-2 production in Jurkat T
cells and thus suggest that 590C SNP may be functionally
associated with the susceptibility to RA.
4. Discussion
In this study, we show that BTLA is an RA-susceptibility gene
and provide evidence that BTLA is involved in the protection
from autoimmunity in humans. We found a signiﬁcant
association of 590C SNP of BTLA gene with susceptibilityClinical and Developmental Immunology 5
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Figure 1: Disease proﬁles of rheumatoid arthritis patients with 590A/A and 590C SNPs of BTLA gene. Titers of C-reactive protein (CRP),
rheumatoid factor (RF), and matrix metalloproteinase-3 (MMP-3) at the ﬁrst visit to the hospital in RA patients with 590A/A and 590C
(590A/C and C/C); SNPs of BTLA gene are shown.
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Figure 2:Lossofinhibitoryfunctionof590CBTLAonConA-andanti-CD3Ab-inducedIL-2productioninJurkatTcells.(a)FACSanalysis
of BTLA expression in stable transfectants of Jurkat T cells with the retrovirus of 590A BTLA-IRES-GFP (solid line), 590C BTLA-IRES-GFP
(dottedline),orGFP-RV(anegativecontrol;shadedhistogram).BothoftransfectantsexpressBTLAatsimilarlevels.(b)ConA-inducedIL-2
productionfromJurkatTcellsexpressing590ABTLAor590CBTLA.JurkatTcellsexpressing590ABTLAor590CBTLA(5 ×105 cells) were
cocultured with 2 × 105 of HVEM-expressing CHO cells in the presence of various concentrations of concanavalin A (ConA). Twenty-four
hours later, IL-2 levels in the supernatants were measured by ELISA. Representative data from three independent experiments are shown.
(c) Anti-CD3 Ab-induced IL-2 production from Jurkat T cells expressing 590A BTLA or 590C BTLA. Jurkat T cells expressing 590A BTLA
or 590C BTLA (5 × 105 cells) were stimulated with immobilized anti-CD3 Ab (0.2 μg/ml) and various concentrations of immobilized anti-
BTLA Ab (MIH26) (0–20 μg/ml) in the presence of anti-CD28 Ab (1 μg/ml). Twenty-four hours later, IL-2 levels in the supernatants were
determined by ELISA. Representative data of the percent IL-2 production from three independent experiments are shown.6 Clinical and Developmental Immunology
to RA, but not to SLE or SS by the case-control association
study (Tables 2 and 3). We also found that the carriage of
590C allele of BTLA gene accelerated the development of
RA. Moreover, we found that inhibitory activity of BTLA on
ConA- and anti-CD3 Ab-induced IL-2 production in Jurkat
T cells is lost by 590A to C conversion (Figures 2(b) and
2(c)).Takentogether,theseresultssuggestthat590CSNPisa
polymorphism that lacks the inhibitory activity of BTLA and
then increases the susceptibility to RA.
We show that a functional polymorphism at #590 on
BTLA gene is associated with susceptibility to RA. Recently,
associations between the polymorphisms of inhibitory core-
ceptors and autoimmune diseases have been reported. SNPs
in CTLA-4 are associated with disease risk in Grave’s disease,
autoimmune hypothyroidism, and type I diabetes [15].
SNP in PD-1 is associated with susceptibility to SLE [11]
and RA [12]. We show here that SNP in BTLA, the third
member of inhibitory coreceptors, is associated with RA.
Taken together, these ﬁndings suggest that dysfunction of
inhibitory coreceptors is deeply involved in the pathogenesis
of autoimmune diseases in humans.
We demonstrate that 590C BTLA lacks the inhibitory
function on ConA- and anti-CD3 Ab-induced IL-2 produc-
tion (Figures 2(b) and 2(c)). On the other hand, we found
that there was no apparent diﬀerence in the surface levels of
BTLA between transfectants of 590C BTLA and 590A BTLA
(Figure 2(a)). Therefore, it is suggested that the alteration
at #590 nucleotide with asparagine to threonine in the
intracellulardomainofBTLAmayinterferewithitssignaling
rather than its expression, presumably by downregulating
the association of an undeﬁned kinase that phosphorylates
BTLA or SHP-1/SHP-2. This possibility needs to be tested
by evaluating the ability of 590C BTLA protein to be
phosphorylated or associated with SHP-1/SHP-2 in response
to ligand-mediated activation.
We found that when Jurkat T cells expressing 590C
BTLA were stimulated with ConA in the presence of HVEM-
expressing CHO cells, these cells exhibited rather enhanced
IL-2 production as compared with cells infected with control
retrovirus (Figure 2(b)). In contrast, when Jurkat T cells
expressing 590C BTLA were stimulated with immobilized
anti-CD3 Ab in the presence of anti-BTLA Ab, these cells
didnotshowenhancedIL-2production(Figure 2(c)).Inthis
r e g a r d ,H V E M ,al i g a n df o rB T L A[ 23, 24], has been origi-
nally identiﬁed as a receptor for the TNF family members,
LIGHTandLTα[31],andhasbeendemonstratedtotransmit
a costimulatory signal in T cells through the interaction with
LIGHT and LTα [32, 33]. Because it has been shown that
HVEMandLIGHTareexpressedonJurkatTcellsafterTCR-
mediated activation [34, 35] and because BTLA is suggested
to form a ternary complex with HVEM and LIGHT and
then may enhance LIGHT-HVEM signaling [24, 36], the
expression of 590C BTLA not only lacks the function as an
inhibitory coreceptor, but may enhance IL-2 production by
this reverse costimulatory signaling through HVEM.
It is also possible that a change from asparagine to
threonine in 590C BTLA may make BTLA a substrate of
serine/threonine kinases and transduce stimulatory signals
in association with HVEM, because sequence around
threonine exhibits an XRXXT motif, which was reported to
be phosphorylated by serine/threonine kinases such as Akt
and CaMK II [37]. This possibility needs to be addressed
by evaluating threonine phosphorylation of 590C BTLA in
response to HVEM-mediated activation.
Many studies of multiple populations have supported
a strong association between HLA class II and RA [38–
41]. However, disease susceptibility regions for RA, other
than HLA, are not yet completely understood. Genome-wide
linkage study conducted by Corn´ elis et al. identiﬁed only one
signiﬁcant RA susceptibility locus which was located within
chromosome 3q13 [42] and predicted that the candidate
genes in this region might be CD80 and CD86. However,
the association between RA and polymorphisms in CD80
and CD86 was not observed [43]. On the other hand, by
taking a candidate gene approach, we could identify BTLA
as a susceptibility gene for RA. Although the functional
analyses of T cells expressing 590C BTLA or 590A BTLA
in RA patients as well as in healthy controls are needed to
reinforce our ﬁndings, we assume that a susceptibility gene
for RA in chromosome 3q13 is BTLA [16].
Given that BTLA is associated with RA (Tables 2 and 3),
wehaveexploredindetailthearthriticchangesintheextrem-
ities in aged BTLA−/− mice. However, although BTLA−/−
mice spontaneously develop autoantibodies and autoim-
mune hepatitis-like disease with age [25], BTLA−/− mice did
not show any signiﬁcant lesions resembling synovitis in RA
patients (data not shown). The lack of RA-like phenotype in
BTLA−/− mice may be explained by the diﬀerent expression
pattern of BTLA in mice and humans in hematopoietic cell
population [44, 45]. It is also possible that BTLA 590C may
exhibit a costimulatory activity instead of a coinhibitory
activity in some situations, and such activity may cause the
diﬀerence in the arthritic changes in humans and mice.
We have shown that #590 SNP, but not #800 SNP,
of BTLA gene is associated with RA susceptibility in the
Japanese population (Tables 2 and 3). In contrast, Lin
et al. have recently reported that SNP at #800 of BTLA
gene is associated with RA susceptibility in the Taiwanese
population [26]. They have reported that homozygous
genotype (800 C/C or 800 T/T) of BTLA is the risk of RA
comparing heterozygous genotype (800 T/C). The reason for
this disparity is currently unknown, and further studies are
required for addressing the disparity between these studies.
Inconclusion,wehaveshownthatthealterationofBTLA
function by 590C SNP is involved in the pathogenesis of RA.
Our data also give a new insight to the understanding of the
pathogenesis of RA and may provide a clue to the application
of BTLA for the treatment of RA.
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